NASDAQ:PASG Passage Bio (PASG) Stock Price, News & Analysis $4.04 +0.03 (+0.62%) As of 11:29 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Passage Bio Stock (NASDAQ:PASG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Passage Bio alerts:Sign Up Key Stats Today's Range$3.95▼$3.9550-Day Range$3.32▼$5.0452-Week Range$3.29▼$20.00Volume529 shsAverage Volume59,025 shsMarket Capitalization$12.99 millionP/E RatioN/ADividend YieldN/APrice Target$13.25Consensus RatingHold Company Overview Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies to develop treatments intended to address the underlying genetic causes of severe neurological and neurodegenerative disorders. Its research programs have included PBGM01, an investigational gene therapy for GM1 gangliosidosis, a rare inherited disorder caused by mutations affecting the GLB1 gene. Passage Bio has also advanced programs for other conditions, including Krabbe disease and frontotemporal dementia. These therapies remain investigational and have not been approved for commercial use. Passage Bio was founded in 2018 and is based in Philadelphia, Pennsylvania. The company was established with connections to the University of Pennsylvania’s Gene Therapy Program and has conducted development activities through clinical and research collaborations. Passage Bio’s programs are intended for patients in markets where the company can obtain regulatory authorization and establish clinical or commercial access. The company is led by William Chou, who has served as chief executive officer. As a development-stage biotechnology company, Passage Bio’s operations are primarily focused on research, clinical development, regulatory activities and collaboration rather than the sale of marketed products.AI Generated. May Contain Errors. Read More Passage Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScorePASG MarketRank™: 2.656700760555 of 5 starsPassage Bio scored higher than 53% of companies evaluated by MarketBeat, and ranked 355th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingPassage Bio has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 2 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialPassage Bio has a consensus price target of $13.25, representing about 230.4% upside from its current price of $4.01.Amount of Analyst CoveragePassage Bio has only been the subject of 1 research reports in the past 90 days.Read more about Passage Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Passage Bio are expected to decrease in the coming year, from ($9.78) to ($10.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 200.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.62% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 3.99, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently decreased by 28.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.43 News SentimentPassage Bio has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Passage Bio this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have not sold or bought any company stock.Percentage Held by Insiders4.90% of the stock of Passage Bio is held by insiders.Percentage Held by Institutions53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Passage Bio's insider trading history. Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PASG Stock News HeadlinesPassage Bio (PASG) Projected to Post Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.comPassage Bio’s PBFT02 Trial Termination Raises New Questions for PASG InvestorsOctober 29, 2026 | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 13 at 1:00 AM | Porter & Company (Ad)PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its ShareholdersOctober 21, 2026 | businesswire.com$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWDOctober 20, 2026 | globenewswire.comPassage Bio Amends Remix Merger, Private Financing TermsSeptember 3, 2026 | tipranks.comPassage Bio, Inc. (PASG) M&A Call Prepared Remarks TranscriptJune 25, 2026 | seekingalpha.comPASG stock slumps 16% after-hours — what’s driving the selloff?June 24, 2026 | msn.comSee More Headlines PASG Stock Analysis - Frequently Asked Questions How have PASG shares performed this year? Passage Bio's stock was trading at $11.80 at the beginning of the year. Since then, PASG shares have decreased by 66.0% and is now trading at $4.01. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($1.47) EPS for the quarter, meeting analysts' consensus estimates of ($1.47). When did Passage Bio's stock split? Passage Bio's stock reverse split on the morning of Monday, July 14th 2025.The 1-20 reverse split was announced on Thursday, July 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Passage Bio IPO? Passage Bio (PASG) raised $204 million in an initial public offering on Friday, February 28th 2020. The company issued 12,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Cabaletta Bio (CABA), Precision BioSciences (DTIL), Black Diamond Therapeutics (BDTX), LogicBio Therapeutics (LOGC) and HOOKIPA Pharma (HOOK). Company Calendar Last Earnings11/10/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PASG's financial health is in the Red zone, according to TradeSmith. PASG has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PASG CIK1787297 Webwww.passagebio.com Phone(267) 866-0312FaxN/AEmployees24Year Founded2018Price Target and Rating Average Price Target for Passage Bio$13.25 High Price Target$23.00 Low Price Target$7.00 Potential Upside/Downside+228.4%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($11.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-377.94% Return on Assets-91.44% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book201.75Miscellaneous Outstanding Shares3,220,000Free Float3,060,000Market Cap$12.99 million OptionableNo Data Beta1.51 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PASG) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
